Skip to main content
Category

Research

targeted oncology
ResearchTreatments

Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC

*January 25, 2019* Targeted Oncology, Tony Berberabe. Patients who continued receiving osimertinib (Tagrisso) after their non–small cell lung cancer (NSCLC) had progressed demonstrated a prolonged benefit beyond the initial progression event, according to a retrospective analysis of 118 patients from The University of Texas MD Anderson Cancer Center (MDACC) and the…
laurabbook@gmail.com
February 3, 2019
ResearchTreatments

PATIENTS LAUNCH NEW STUDY TO SHED LIGHT ON EGFR-POSITIVE LUNG CANCERS

Scientists, physicians and patients collaborate to improve treatment for rare cancer SAN CARLOS, CA (November 14, 2018) — The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR Resisters today announced the launch of a new study to create a novel bank of patient derived xenograft (PDX) models to help researchers better understand why patients living…
laurabbook@gmail.com
November 22, 2018
ResearchTreatments

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

*NATURE COMMUNICATIONS | (2018) 9:4655 | DOI: 10.1038/s41467-018-07078-0 | www.nature.com/naturecommunications * The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. In a subgroup of these patients we identified an association between selection of EGFR T790M-negative but EGFR G724S-positive subclones and osimertinib resistance.…
laurabbook@gmail.com
November 22, 2018
Research

Bring Hope Home

http://egfrcancer.org/wp-content/uploads/2018/06/bring-hope-home-.jpg June 19th Living Room "Resistance to Targeted Therapy" Dr. Colin Blakely will be discussing all the questions about progression in your lung cancer and where to go and what to do. Dr. Blakely will be talking about what is happening in the research field from next generation therapies after progression from your…
cece
June 18, 2018